Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis

Bepotastine besilate 1.5% solution is an H(1)-antihistamine recently approved by the Food and Drug Administration for the topical treatment of ocular itching associated with allergic conjunctivitis. Several clinical studies have demonstrated its safety as well as its efficacy versus placebo. This re...

Descripción completa

Detalles Bibliográficos
Autores principales: Wingard, Jeremy B, Mah, Francis S
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046989/
https://www.ncbi.nlm.nih.gov/pubmed/21386912
http://dx.doi.org/10.2147/OPTH.S8665
_version_ 1782199012594548736
author Wingard, Jeremy B
Mah, Francis S
author_facet Wingard, Jeremy B
Mah, Francis S
author_sort Wingard, Jeremy B
collection PubMed
description Bepotastine besilate 1.5% solution is an H(1)-antihistamine recently approved by the Food and Drug Administration for the topical treatment of ocular itching associated with allergic conjunctivitis. Several clinical studies have demonstrated its safety as well as its efficacy versus placebo. This review finds that bepotastine besilate 1.5% solution is a suitable alternative to other agents within the class of H(1)-antihistamines, but there are no clinical trial data to suggest that it holds any specific advantages over other agents.
format Text
id pubmed-3046989
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-30469892011-03-08 Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis Wingard, Jeremy B Mah, Francis S Clin Ophthalmol Review Bepotastine besilate 1.5% solution is an H(1)-antihistamine recently approved by the Food and Drug Administration for the topical treatment of ocular itching associated with allergic conjunctivitis. Several clinical studies have demonstrated its safety as well as its efficacy versus placebo. This review finds that bepotastine besilate 1.5% solution is a suitable alternative to other agents within the class of H(1)-antihistamines, but there are no clinical trial data to suggest that it holds any specific advantages over other agents. Dove Medical Press 2011 2011-02-15 /pmc/articles/PMC3046989/ /pubmed/21386912 http://dx.doi.org/10.2147/OPTH.S8665 Text en © 2011 Wingard and Mah, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.
spellingShingle Review
Wingard, Jeremy B
Mah, Francis S
Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis
title Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis
title_full Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis
title_fullStr Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis
title_full_unstemmed Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis
title_short Critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis
title_sort critical appraisal of bepotastine in the treatment of ocular itching associated with allergic conjunctivitis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3046989/
https://www.ncbi.nlm.nih.gov/pubmed/21386912
http://dx.doi.org/10.2147/OPTH.S8665
work_keys_str_mv AT wingardjeremyb criticalappraisalofbepotastineinthetreatmentofocularitchingassociatedwithallergicconjunctivitis
AT mahfranciss criticalappraisalofbepotastineinthetreatmentofocularitchingassociatedwithallergicconjunctivitis

Ejemplares similares